Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Journal of Autism and Developmental Disorders 2/2007

01-02-2007 | Original Paper

Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

Auteurs: Gahan J. Pandina, Cynthia A. Bossie, Eriene Youssef, Young Zhu, Fiona Dunbar

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 2/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Subgroup analysis of children (5–12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (= 27) or placebo (= 28); mean baseline ABC-I ( ± SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( ± SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( ± SD): −13.4 (1.5) vs. −7.2 (1.4), < 0.05; ES = −0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism.
Literatuur
go back to reference Aman, M. G. (2004). Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Seminars in Pediatric Neurology, 11, 225–228. PubMedCrossRef Aman, M. G. (2004). Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Seminars in Pediatric Neurology, 11, 225–228. PubMedCrossRef
go back to reference Aman, M. G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K. D., et al. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9, 36–47. PubMed Aman, M. G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K. D., et al. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9, 36–47. PubMed
go back to reference Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491. PubMed Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485–491. PubMed
go back to reference Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41–57. PubMedCrossRef Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17, 41–57. PubMedCrossRef
go back to reference American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.
go back to reference American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders. Washington: American Psychiatric Press. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders. Washington: American Psychiatric Press.
go back to reference Arnold, L. E., Vitiello, B., McDougle, C., Scahill, L., Shah, B., Gonzalez, N. M., et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1443–1450. PubMedCrossRef Arnold, L. E., Vitiello, B., McDougle, C., Scahill, L., Shah, B., Gonzalez, N. M., et al. (2003). Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1443–1450. PubMedCrossRef
go back to reference Carter, A. S., Volmar, F. R., Sparrow, S. S., Wang, J. J., Lord, C., Dawson, G., et al. (1998). The Vineland Adaptive Behavioral Scales: Supplementary norms of individuals with autism. Journal of Autism and Developmental Disorders, 28, 287–302. PubMedCrossRef Carter, A. S., Volmar, F. R., Sparrow, S. S., Wang, J. J., Lord, C., Dawson, G., et al. (1998). The Vineland Adaptive Behavioral Scales: Supplementary norms of individuals with autism. Journal of Autism and Developmental Disorders, 28, 287–302. PubMedCrossRef
go back to reference Chez, M. G., Memon, S., & Hung, P. C. (2004). Neurologic treatment strategies in autism: An overview of medical intervention strategies. Seminars in Pediatric Neurology, 11, 229–235. PubMedCrossRef Chez, M. G., Memon, S., & Hung, P. C. (2004). Neurologic treatment strategies in autism: An overview of medical intervention strategies. Seminars in Pediatric Neurology, 11, 229–235. PubMedCrossRef
go back to reference Chouinard, G., Ross-Chouinard, A., Annable, L., & Jones, B. D. (1980). Extrapyramidal symptom rating scale. The Canadian Journal of Neurological Sciences, 7, 233. Chouinard, G., Ross-Chouinard, A., Annable, L., & Jones, B. D. (1980). Extrapyramidal symptom rating scale. The Canadian Journal of Neurological Sciences, 7, 233.
go back to reference Dunbar, F., Kusumakar, V., Daneman, D., & Schultz, M. (2004). Growth and sexual maturation during long-term treatment with risperidone. American Journal of Psychiatry, 161, 918–920. PubMedCrossRef Dunbar, F., Kusumakar, V., Daneman, D., & Schultz, M. (2004). Growth and sexual maturation during long-term treatment with risperidone. American Journal of Psychiatry, 161, 918–920. PubMedCrossRef
go back to reference Findling, R., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry, 64, 1362–1369. PubMedCrossRef Findling, R., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry, 64, 1362–1369. PubMedCrossRef
go back to reference Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: An update. Journal of Autism and Developmental Disorders, 33, 365–382. PubMedCrossRef Fombonne, E. (2003). Epidemiological surveys of autism and other pervasive developmental disorders: An update. Journal of Autism and Developmental Disorders, 33, 365–382. PubMedCrossRef
go back to reference Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D’Arrigo, C., Calamoneri, F., & Spina, E. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14, 39–47. PubMedCrossRef Gagliano, A., Germano, E., Pustorino, G., Impallomeni, C., D’Arrigo, C., Calamoneri, F., & Spina, E. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability, and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14, 39–47. PubMedCrossRef
go back to reference Horner, R. H., Carr, E. G., Strain, P. S., Todd, A. W., & Reed, H. K. (2002). Problem behavior interventions for young children with autism: A research synthesis. Journal of Autism and Developmental Disorders, 32, 423–446. PubMedCrossRef Horner, R. H., Carr, E. G., Strain, P. S., Todd, A. W., & Reed, H. K. (2002). Problem behavior interventions for young children with autism: A research synthesis. Journal of Autism and Developmental Disorders, 32, 423–446. PubMedCrossRef
go back to reference Malone, R. P., Maislin, G., Choudhury, M. S., Gifford, C., & Delaney, M. A. (2002). Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 140–147. PubMedCrossRef Malone, R. P., Maislin, G., Choudhury, M. S., Gifford, C., & Delaney, M. A. (2002). Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 140–147. PubMedCrossRef
go back to reference Masi, G. (2004). Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs, 18, 1031–1052. PubMedCrossRef Masi, G. (2004). Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs, 18, 1031–1052. PubMedCrossRef
go back to reference Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2003). A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. The Journal of Clinical Psychiatry, 64, 1039–1047. PubMed Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2003). A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. The Journal of Clinical Psychiatry, 64, 1039–1047. PubMed
go back to reference McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al., Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321. PubMedCrossRef McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al., Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321. PubMedCrossRef
go back to reference McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. The American Journal of Psychiatry, 162, 1142–1148. PubMedCrossRef McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. The American Journal of Psychiatry, 162, 1142–1148. PubMedCrossRef
go back to reference Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 372–376. PubMedCrossRef Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 372–376. PubMedCrossRef
go back to reference Posey, D. J., & McDougle, C. J. (2000). The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review of Psychiatry, 8, 45–63. PubMedCrossRef Posey, D. J., & McDougle, C. J. (2000). The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review of Psychiatry, 8, 45–63. PubMedCrossRef
go back to reference Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled withdrawal study of risperidone in maintenance treatment of children and adolescents with disruptive behaviour disorder. American Journal of Psychiatry, 163, 402–410. PubMedCrossRef Reyes, M., Buitelaar, J., Toren, P., Augustyns, I., & Eerdekens, M. (2006). A randomized, double-blind, placebo-controlled withdrawal study of risperidone in maintenance treatment of children and adolescents with disruptive behaviour disorder. American Journal of Psychiatry, 163, 402–410. PubMedCrossRef
go back to reference Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980). Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10, 91–103. PubMedCrossRef Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980). Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10, 91–103. PubMedCrossRef
go back to reference Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. PubMedCrossRef Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., & Dunbar, F. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. PubMedCrossRef
go back to reference Sparrow, S., & Cicchetti, D. (1985). Diagnostic uses of the Vineland Adaptive Behavior Scales. Journal of Pediatric Psychology, 10, 215–225. PubMedCrossRef Sparrow, S., & Cicchetti, D. (1985). Diagnostic uses of the Vineland Adaptive Behavior Scales. Journal of Pediatric Psychology, 10, 215–225. PubMedCrossRef
go back to reference Tassé, M. J., Aman, M. G., & Rojahn, J. (1996). The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities, 17, 59–75. PubMedCrossRef Tassé, M. J., Aman, M. G., & Rojahn, J. (1996). The Nisonger Child Behavior Rating Form: Age and gender effects and norms. Research in Developmental Disabilities, 17, 59–75. PubMedCrossRef
go back to reference Yeargin-Allsopp, M., Rice, C., Karapurkar, T., Doernberg, N., Boyle, C., & Murphy, C. (2003). Prevalence of autism in a US metropolitan area. JAMA: The Journal of the American Medical Association, 289, 49–55. CrossRef Yeargin-Allsopp, M., Rice, C., Karapurkar, T., Doernberg, N., Boyle, C., & Murphy, C. (2003). Prevalence of autism in a US metropolitan area. JAMA: The Journal of the American Medical Association, 289, 49–55. CrossRef
Metagegevens
Titel
Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial
Auteurs
Gahan J. Pandina
Cynthia A. Bossie
Eriene Youssef
Young Zhu
Fiona Dunbar
Publicatiedatum
01-02-2007
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 2/2007
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-006-0234-7